







Dear Doctor You are cordially invited to attend

Meningitis disease burden in high risk population

that will be



Monday 26TH Feb.



7:00 PM Bahrain Time



Radisson Blu - Bahrain Venue:Andalus Ballroom

Dr. Islam El-Amir



Dr. Jameela Al-SalmanAssociate Professor of medicine-Arabian Gulf University
Infectious Disease,Internal medicine and Geriatric Consultant
Certified in infection control



Dr. Jaffer Abdul JabbarConsultant Hematology, SMC. A member of the hematology management board at SMC, MOH Bahrain from 2007-2013. Chief Resident Coordinator for the Oncology Department at MOH, Bahrain, 2007-2013. SCD Team Leader at Bahrain MOH, 2014 till present.
SCD management Board member since 2014. Training Coordinator for HBDC since 2016. Member of Bahrain MOH transfusion committee.



07:10 - 07:40 pm

Islam El-Amir Medical Affairs Manager, Vaccine, GSK

AGENDA

Timing	Іоріс	Speaker

7:00 – 07:10 pm Opening Dr.Jameela Al-Salman

Deep dive in Meningitis

prevention

disease burden and

07:40 - 08:10 pm sickle cell disease Dr.Jaffer Abdul Jabbar

08:10 – 08:25 pm Q&A Panel Discussion

FOR HEALTHCARE PROFESSIONAL ONLY IN Bahrain

For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via gulf.ProductQualityComplaints@gsk.com
This message is for the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.

You are receiving this email as we have your details as a healthcare professional. Email programs can consider these messages as junk mail and may automatically put them in your bulk or junk folder. To ensure the emails you requested are delivered to your inbox, add our email address to your address book. Please do not reply to this message as these emails are not monitored.

This email is intended for Kuwait healthcare professionals only.

About this email: GSK Gulf has selected this email to be of interest to you in line with your email preferences, which you can edit or <u>unsubscribe</u> from at any time.

Please do not reply to this message as this is an inactive mailbox and your message will be automatically deleted. If you have any questions or comments please <u>contact us</u>.

to maintain the security of systems, and to protect our staff, customers, and business partners from cyber threats and loss of information. These monitoring activities include checks for offensive materials, viruses, and other malignant code, and unauthorized or unlawful activity.

GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws. You can learn about the information that we may

About your privacy: GSK may monitor our technology tools and services (including email, phone, and other communications sent to and from GSK) in order

process about you, and how we use your information <u>here</u>.

You can also view our <u>terms of use</u>.

Trademarks are owned by or licensed to the GSK group of companies.

Copyright © GlaxoSmithKline 2024. All rights reserved.

The previous content information must be used only by healthcare professionals from Bahrain in addition to the GSK safety reporting email.

This event is intended for scientific exchange in response to requests from Bahrain Infectious Disease association and is non-promotional in nature.

The information shared in this event is intended for healthcare professionals from Bahrain only, where the 4C Men B is not approved by the competent

health authority.

